2017 VC Deals

A Sampling of the Year's Venture Capital Transactions

February 20, 2018



In 2017 Morse once again represented its clients in a range of venture capital transactions, including convertible note financings, equity investments, and sales of preferred stock. Our VC attorneys counseled companies in an array of industries, including biotechnology, custom clothing, and medical devices, among others.

ENBIOTIX	Represented **EnBiotix**, a product-focused bioengineering company commercializing anti-infective inventions, in its Convertible Note Financing.
FUEL FOR FIRE®	Represented **Fuel For Fire**, a health and nutrition retailer, in the Sale of Series D Preferred Stock.
ORIONIS BIOSCIENCES	Represented **Orionis Biosciences**, a company specializing in the development of new drugs for the treatment of certain autoimmune diseases and pathologies linked to certain types of cancer, in its Bridge Note Financing.

	Represented **Privy**, a platform that empowers marketers to build more customer relationships, in its Series Seed-2 Financing.
	Represented **Cristcot**, a global life sciences company focusing on unique drug delivery systems, combination products and specialty drug formulations, in its Convertible Note Financing.
	Represented **Manus Bio**, an interdisciplinary team dedicated to the sustainable production of quality plant-based ingredients, in its Series A Financing.
	Represented **Accomplice Ventures**, a seed-led venture capital firm, in its Equity Investment into Tive, Inc.
	Represented **iSpecimen**, the marketplace for human biospecimens, in its Convertible Note Financing.

	Represented **Novellus**, an early stage biotechnology company, in its Convertible Note Financing.
	Represented **SciAps**, a Boston-based instrumentation company specializing in portable analytical instruments, in its Series C Financing.
	Represented **Connected Home Care**, a provider of non-medical home care and companionship services for elders who want to live at home, in its Series A Follow-On Financing.
	Represented **dRx Capital**, an investor in early-stage companies in the digital medicine industry, in its Series C-1 Follow-On Financing of Omada Health.
	Represented **First Light Biosciences**, a developer of automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections, in a Series A Preferred Financing.

BOW & DRAPE NEW YORK	Represented **Bow & Drape**, a custom clothing retailer, in its Convertible Note Financing.